FrancophonIA/ELRC3.0 huggingface dataset:
English: Relative AUC and Cmax of aliskiren in subjects with renal impairment ranged between 0.8 to 2 times the levels in healthy subjects following single dose administration and at steady state.
Maltese: AUC u Cmax relattivi ta' aliskiren f'individwi b'indeboliment renali kellhom medda ta' bejn 0.8 sa darbtejn illivelli f'individwi b'saħħithom wara li ngħatat doża waħda u fi stat fiss.
English: Pregnancy and breast-feeding
Maltese: Linejarità/nuqqas ta' linejarità
English: Do not use Tekturna after the expiry date which is stated on the carton and blister.
Maltese: Tużax Tekturna wara d-data ta' skadenza li tidher fuq il-kartuna u l-folja.
English: What Tekturna looks like and contents of the pack Tekturna 300 mg film coated tablets are light-red, biconvex, ovaloid tablets, imprinted “IU” on one side and “NVR” on the other side.
Maltese: Id-Dehra ta' Tekturna u l-kontenuti tal-pakkett Tekturna 300 mg pilloli miksijin b'rita huma pilloli aħmar ċar, konvessi miż-żewġ naħat, f'għamla ovali, ittimbrati ‘IU' fuq naħa u ‘NVR' fuq in-naħa l-oħra.
English: NAME OF THE MEDICINAL PRODUCT Tekturna 150 mg film-coated tablets
Maltese: Id-doża irrikkmandata ta' Tekturna hija 150 mg darba kuljum.
English: When administered with atorvastatin, steady-state Tekturna AUC and Cmax increased by 50%.
Maltese: Meta ngħata ma' atorvastatin, lAUC u Cmax fi stat fiss ta' Tekturna żdiedu b'50%.
English: Due to the lack of data a potential interaction between grapefruit juice and aliskiren cannot be excluded.
Maltese: Minħabba nuqqas ta' dejta interazzjonijiet li jista' jkun hemm bejn il-meraq tal-grejpfrut u aliskiren ma jistgħux jiġu esklużi.
English: Mechanisms responsible for deviation from linearity have not been identified.
Maltese: Mekkaniżmi responsabbli għad-devjazzjoni mill-linejarità ma ġewx identifikati.
English: EMA/78333/2016 EMEA/H/C/004037
Maltese: EMA/78333/2016 EMA/H/C/004037
English: It is a ‘generic medicine'.
Maltese: Din hija "mediċina ġenerika".
English: Amlodipine/Valsartan Mylan is available as tablets (5 mg amlodipine and 80 mg valsartan; 5 mg amlodipine and 160 mg valsartan; 10 mg amlodipine and 160 mg valsartan).
Maltese: Amlodipine/Valsartan Mylan huwa disponibbli bħala pilloli (5 mg amlodipina u 80 mg valsartan; 5 mg amlodipina u 160 mg valsartan; 10 mg amlodipina u 160 mg valsartan).
English: The full EPAR for Amlodipine/Valsartan Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Amlodipine is a calcium channel blocker.
Maltese: L-amlodipina hija mblokkatur tal-kanal tal-kalċju.
English: Amlodipine/Valsartan Mylan amlodipine / valsartan
Maltese: Informazzjoni oħra dwar Amlodipine/Valsartan Mylan
English: Amlodipine/Valsartan Mylan contains two active substances, amlodipine and valsartan.
Maltese: Amlodipine/Valsartan Mylan fih żewġ sustanzi attivi, l-amlodipina u l-valsartan.
English: Because Amlodipine/Valsartan Mylan is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Exforge.
Maltese: Billi Amlodipine/Valsartan Mylan huwa mediċina ġenerika, l-istudji fuq in-nies ġew limitati għal testijiet biex jiddeterminaw il-bijoekwivalenza tiegħu mal-mediċina ta' referenza, Exforge.
English: This is a summary of the European public assessment report (EPAR) for Amlodipine/Valsartan Mylan.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Amlodipine/Valsartan Mylan.
English: Because Amlodipine/Valsartan Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Amlodipine/Valsartan Mylan huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: This means that Amlodipine/Valsartan Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exforge.
Maltese: Dan ifisser li Amlodipine/Valsartan Mylan jixbah lill-‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) magħrufa bħala Exforge.
English: How is Amlodipine/Valsartan Mylan used?
Maltese: Kif jintuża Amlodipine/Valsartan Mylan?
English: Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels).
Maltese: II hija vażokostrittur qawwi (sustanza li traqqaq il-vini tad-demm).
English: The Committee recommended that Amlodipine/Valsartan Mylan be approved for use in the EU.
Maltese: Il-Kumitat irrakkomanda li Amlodipine/Valsartan Mylan ikun approvat għall-użu fl-UE.
English: Both are antihypertensive medicines that have been available separately in the European Union (EU) since the mid1990s.
Maltese: It-tnejn huma mediċini kontra l-pressjoni għolja li ilhom disponibbli separatament fl-Unjoni Ewropea (UE) minn nofs is-snin disgħin.
English: A risk management plan has been developed to ensure that Amlodipine/Valsartan Mylan is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Amlodipine/Valsartan Mylan jintuża bl-aktar mod sigur possibbli.
English: By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.
Maltese: Bit-tnaqqis tal-pressjoni tad-demm, jitnaqqsu r-riskji assoċjati ma' pressjoni għolja tad-demm, bħall-puplesija.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Amlodipine/Valsartan Mylan has been shown to have comparable quality and to be bioequivalent/be comparable to Exforge.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) tal-Aġenzija kkonkluda li, skont irrekwiżiti tal-UE, intwera li Amlodipine/Valsartan Mylan għandu kwalità komparabbli u huwa bijoekwivalenti għal Exforge.
English: Why is Amlodipine/Valsartan Mylan approved?
Maltese: Għaliex ġie approvat Amlodipine/Valsartan Mylan?
English: It is recommended that the patient takes amlodipine and valsartan as separate tablets or capsules before switching to the combination tablet.
Maltese: Huwa rrakkomandat li l-pazjent jieħu amlodipina u valsartan bħala pilloli jew kapsuli separati qabel ma jaqleb għall-pillola ta' kombinament.
English: Valsartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Maltese: L-EPAR sħiħ tal-mediċina ta' referenza jinstab ukoll fis-sit web tal-Aġenzija.
English: Further information on HorStem can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/horstem.
Maltese: ema.europa.eu/medicines/veterinary/EPAR/horstem.
English: Other information about HorStem
Maltese: Informazzjoni oħra dwar HorStem
English: HorStem (equine umbilical cord mesenchymal stem cells) EMA/162149/2019
Maltese: HorStem (ċelloli staminali mesenkimali tal-kurdun umbiliku ekwin) EMA/336331/2019
English: HorStem (equine umbilical cord mesenchymal stem cells)
Maltese: HorStem (ċelloli staminali mesenkimali tal-kurdun umbiliku ekwin)
English: Horses were examined at days 14, 35 and 63.
Maltese: Iż-żwiemel ġew eżaminati fl-14-il jum, fil-35 jum u fit-63 jum.
English: HorStem received a marketing authorisation valid throughout the EU on 19 June 2019.
Maltese: HorStem irċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha fi 19/06/2019.
English: Treatment success was a reduction in lameness to a grade of 1 or less, using an accepted scale for equine lameness measurement (scale from 0 to 5, where 0 is nonlame, and 5 is severely lame).
Maltese: Is-suċċess tal-kura kien tnaqqis fiz-zappip għal grad ta' 1 jew inqas, bl-użu ta' skala aċċettata għall-kejl taz-zappip ekwin (skala minn 0 għal 5 fejn 0 huwa lebda zappip, u 5 huwa zappip sever ħafna.
English: Mesenchymal stem cells can have effects on the immune system as well as anti-inflammatory effects and can possess tissue regenerative properties.
Maltese: Iċ-ċelloli staminali mesenkimali jistgħu jkollhom effetti fuq is-sistema immunitarja kif ukoll effetti antiinfjammatorji u jista' jkollhom proprjetajiet ta' riġenerazzjoni tat-tessut.
English: In a field study of horses with mild to moderate osteoarthritis, 16 horses received an injection of HorStem into the affected joint and 17 horses received a placebo (dummy) injection.
Maltese: Fi studju fuq il-post ta' żwiemel b'osteoartrite minn ħafifa sa moderata, 16-il żiemel rċevew injezzjoni ta' HorStem fil-ġog affettwat u 17-il żiemel irċevew injezzjoni plaċebo (finta).
English: In case of severe inflammation, treatment with an anti-inflammatory medicine (NSAID) might be necessary.
Maltese: F'każ ta' infjammazzjoni severa, il-kura b'mediċina antiinfjammatorja (NSAID) tista' tkun neċessarja.
English: The most common side effect with HorStem (which may affect more than 1 in 10 horses) is short-lived synovitis (inflammation of the joint lining) with severe lameness, joint effusion (increased fluid in the joint) and pain on palpation 24 hours after injection.
Maltese: L-effett sekondarju l-aktar komuni b'HorStem (li jista' jaffettwa aktar minn żiemel 1 f'kull għaxart iżwiemel) huwa sinovite (infjammazzjoni tal-kisja tal-ġog) b'zappip sever, effużjoni tal-ġog (żieda filfluwidu fil-ġog) u wġigħ mal-palpazzjoni 24 siegħa wara l-injezzjoni.
English: This overview was last updated in February 2019.
Maltese: Din il-ħarsa ġenerali ġiet aġġornata l-aħħar fi Frar 2019.
English: It contains the active substance equine umbilical cord mesenchymal stem cells.
Maltese: Fih is-sustanza attiva ċelloli staminali mesenkimali talkurdun umbiliku ekwin.
English: What are the risks associated with HorStem?
Maltese: X'inhuma r-riskji assoċjati ma' HorStem?
English: Twelve HorStem treated horses were successfully treated (success rate 75%) at day 63 compared to only 4 of the control group (success rate 25%).
Maltese: Tnax-il żiemel ikkurati b'HorStem ġew ikkurati b'suċċess (rata ta' suċċess ta' 75 %) fit-63 jum meta mqabbla ma' 4 biss tal-grupp ta' kontroll (rata ta' suċċess ta' 25 %).
English: HorStem is a veterinary medicine used to treat lameness associated with mild to moderate degenerative joint disease (osteoarthritis) in horses.
Maltese: HorStem huwa mediċina veterinarja li tintuża għall-kura taz-zappip assoċjat ma' marda deġenerattiva tal-ġogi minn ħafifa sa moderata fiż-żwiemel.
English: How is HorStem used?
Maltese: Kif jaħdem HorStem?
English: HorStem is given only by a veterinarian as a single injection into the affected joint.
Maltese: HorStem jingħata biss minn veterinarju bħala injezzjoni waħda fil-ġog affettwat.
English: Substantial improvement occurs in the next 48 hours with complete resolution in the following two weeks.
Maltese: Fit-48 siegħa ta' wara jseħħ titjib sostanzjali u fil-ġimagħtejn ta' wara sseħħ remissjoni sħiħa.
English: The full EPAR for Hexacima can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This summary was last updated in 05-2016.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'05-2016.
English: Other information about Hexacima
Maltese: Informazzjoni oħra dwar Hexacima
English: The vaccine is ‘adsorbed'.
Maltese: Il-vaċċin jiġi ‘adsorbit'.
English: Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)
Maltese: Difterite, tetnu, pertussi (aċellulari, komponent), epatite B (rDNA), poljomelite (inattivata) u vaċċin konjugat tal-Haemophilus influenzae tip b (assorbit)
English: A subsequent study involving 455 children looked at the longer-term persistence of protective antibodies up to 3 years after a booster dose with Hexacima, and another study in 1,336 children evaluated the response to different lots of the vaccine and what happened when it was given with vaccines for infections caused by the bacterium Streptococcus pneumoniae (Prevenar) and rotavirus (Rotarix).
Maltese: Studju sussegwenti li involva lil 455 tifel u tifla ħares lejn il-persistenza fit-tul tal-antikorpi protettivi sa 3 snin wara li ngħatat doża booster b'Hexacima, u studju ieħor f'1,336 tifel u tifla evalwa r-rispons għal lottijiet differenti tal-vaċċin u x'ġara meta ngħata ma' vaċċini għal infezzjonijiet ikkaġunati mill-batterju Streptococcus pneumoniae (Prevenar) u rotavirus (Rotarix).
English: This is a summary of the European public assessment report (EPAR) for Hexacima.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Hexacima.
English: The two-dose vaccination schedule was investigated in an additional main study involving 554 children.
Maltese: L-iskeda ta' tilqim f'żewġ dożi ġiet investigata fi studju ewlieni addizzjonali li involva 554 tifel u tifla.
English: Hexacima is a vaccine.
Maltese: Hexacima huwa vaċċin.
English: Why is Hexacima approved?
Maltese: Għalfejn ġie approvat Hexacima?
English: • invasive diseases (such as meningitis) caused by H. influenzae type b bacteria.
Maltese: • mard invażiv (bħall-meninġite) ikkaġunat minn batterji H. influenzae tip b.
English: What are the risks associated with Hexacima?
Maltese: X'inhuma r-riskji assoċjati ma' Hexacima?
English: The CHMP noted that Hexacima has been shown to produce protective antibody levels against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and H. influenzae type b infections in children between six weeks and two years of age regardless of ethnicity.
Maltese: Is-CHMP innota li Hexacima ntwera li jipproduċi livelli ta' antikorpi protettivi kontra l-infezzjonijiet taddifterite, it-tetnu, il-pertussi, l-epatite B, il-poljomelite u H. influenzae tip b fi tfal ta' bejn sitt ġimgħat u sentejn tkun xi tkun l-etniċità.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Hexacima on 17 April 2013.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Hexacima valida fl-Unjoni Ewropea kollha fis-17 ta' April 2013.
English: Hexacima is a vaccine containing active substances derived from diphtheria, tetanus, pertussis and Haemophilus influenzae type b bacteria, the hepatitis B virus, and inactivated polioviruses.
Maltese: Hexacima huwa vaċċin li fih is-sustanzi attivi li ġejjin minn difterite, tetnu, pertussi u batterji Haemophilus influenzae tip b, il-virus tal-epatite B, u polivirusijiet inattivati.
English: The effects were compared with a combination of separate vaccines designed to protect against the diseases included in Hexacima.
Maltese: L-effetti tqabblu ma' kombinazzjoni ta' vaċċini separati mfassla sabiex jipproteġu kontra l-mard inkluż f'Hexacima.
English: In the study, children who received Hexacima produced a similar antibody response to those who received a comparator vaccine (Infanrix hexa), when given as a two-dose schedule followed by a booster 6 months later.
Maltese: Flistudju, it-tfal li ħadu Hexacima pproduċew rispons tal-antikorpi li kien simili għal dak li kellhom it-tfal li ħadu vaċċin komparatur (Infanrix hexa), meta ngħataw skeda f'żewġ dożi segwita minn booster 6 xhur wara.
English: Hexacima has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local vaccination schedules.
Maltese: Hexacima ġie studjat f'bosta pajjiżi madwar id-dinja fi 12-il studju ewlieni li involvew aktar minn 3,400 tifel u tifla ta' bejn sitt ġimgħat u sentejn li ngħataw tliet dożi tal-vaċċin matul l-ewwel sitt xhur ta' ħajjithom skont skedi lokali differenti ta' tilqim.
English: Regarding safety, the CHMP considered that Hexacima's overall safety profile is similar to other vaccines, although Hexacima is more likely than similar vaccines to cause reactions (mainly at the injection site).
Maltese: Fir-rigward tas-sigurtà, is-CHMP ikkunsidra li l-profil tas-sigurtà ġenerali ta' Hexacima huwa simili għal dawk ta' vaċċini oħra, għalkemm Hexacima għandu probabilità ogħla minn vaċċini simili li jikkaġuna reazzjonijiet (l-aktar fis-sit tal-injezzjoni).
English: The most common side effects with Hexacima include pain and redness at the site of injection, irritability and crying.
Maltese: L-effetti sekondarji l-aktar komuni b'Hexacima jinkludu wġigħ u ħmura fis-sit tal-injezzjoni, irritabilità u biki.
English: The studies showed that protective antibody levels against the various diseases developed in between 90 and 100% of children after the first three doses of Hexacima; protection was maintained or improved when a booster dose was given.
Maltese: L-istudji wrew li livelli ta' antikorpi protettivi kontra l-mard differenti żviluppaw f'bejn 90% u 100% tat-tfal wara l-ewwel tliet dożi ta' Hexacima; il-protezzjoni nżammet jew tjiebet meta ngħatat doża booster.
English: How is Hexacima used?
Maltese: Kif jaħdem Hexacima?
English: How does Hexacima work?
Maltese: Kif jintuża Hexacima?
English: Hexacima must not be used in children who have ever had an allergic reaction to Hexacima or a vaccine containing the same components, including substances used during the manufacture of the vaccine and which may be found at extremely low levels (such as the antibiotics neomycin or streptomycin).
Maltese: Hexacima ma għandux jintuża fi tfal li xi darba kellhom reazzjoni allerġika għal Hexacima jew għal vaċċin li fih l-istess komponenti, inklużi sustanzi użati matul il-manifattura tal-vaċċin u li jistgħu jinsabu f'livelli estremament baxxi (bħall-antibijotiċi neomycin jew streptomycin).
English: These studies showed that Hexacima produces similar antibody profiles over time to comparable vaccines, and that the vaccine can be given at the same time as Prevenar and Rotarix.
Maltese: Dawn l-istudji wrew li maż-żmien Hexacima jipproduċi profili tal-antikorpi simili għal vaċċini paragunabbli, u li l-vaċċin jista' jingħata flistess ħin ma' Prevenar u Rotarix.
English: For the full list of all side effects reported with Hexacima, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Hexacima, ara l-fuljett ta' tagħrif.
English: Rebetol dose (mg/kg)
Maltese: Rebetol (mg/kg)
English: Genotype 2/3 88.9 (72/81)
Maltese: Ġenotip 2/3 88.9 (72/81)
English: Genotype 1/4 59.7 (129/216) 51.2 (66/129)
Maltese: Ġenotip 1/4 59.7 (129/216) 51.2 (66/129)
English: F4
Maltese: F3 F4
English: Female: dysmenorrhoea
Maltese: Mara: dismenorreja
English: Nephrotic syndrome*
Maltese: Sindrome nefrotika*
English: Nucleoside analogues
Maltese: Analogi ta' nukleosid
English: Hard capsule (capsule)
Maltese: Kapsula iebsa (kapsula)
English: *AUC12 (ng.hr/mL) for Rebetol; AUC0-24 (IU.hr/mL) for interferon alfa-2b
Maltese: *AUC12 (ng.hr/mL) għal Rebetol; AUC0-24 (IU.hr/mL) għal interferon alfa-2b
English: Bipolar disorder*
Maltese: Disturbi bipolari*
English: Overall Response a (n = 118)
Maltese: (n = 118)
English: Overall Population*
Maltese: Popolazzjoni globali*
English: Contains Sorbitol liquid (crystallising), sucrose.
Maltese: TA' EĊĊIPJENTI Fih: Sorbitol liquid (crystallising), sucrose.
English: Tmax (hr) Cmax (ng/mL) AUC* Apparent clearance L/hr/kg
Maltese: Tmax (hr) Cmax (ng/mL) AUC*
English: Male: impotence, prostatitis, erectile dysfunction.
Maltese: Raġel: impotenza, prostatite, funzjoni ħażina tal-erezzjoni.
English: Seizure (convulsion)*
Maltese: Aċċessjoni (konvulżjoni)*
English: Genotype 1 (n = 92) Genotype 2/3/4 (n = 26)
Maltese: (n = 118) Ġenotip 1 (n = 92) Ġenotip 2/3/4 (n = 26)
English: Packs of 84, 112, 140 and 168 capsules.
Maltese: Pakketti ta' 84, 112, 140 u 168 kapsula.
English: Tachycardia, palpitations
Maltese: Takikardija, palpitazzjonijiet
English: HCV-RNA negative
Maltese: HCV-RNA negattiv 834
English: Pharmacologically, Rebetol increases phosphorylated metabolites of purine nucleosides in vitro.
Maltese: Farmakoloġikament, Rebetol iżid il-metaboliti fosforilati tan-nukleosid tal-purina in vitro.
English: Rebetol contains the active substance ribavirin.
Maltese: Rebetol fih is-sustanza attiva ribavirin.
English: • Haemoglobin
Maltese: • Emoglobina
English: In this subgroup, there was a 56 % (463/823) sustained virological response rate.
Maltese: F'dan is-sottogrupp, kien hemm rata ta' rispons virloġiku sostnut ta' 56 % (463/823).
English: Mitochondrial toxicity and lactic acidosis:
Maltese: Tossiċità mitokondrijali u aċidożi lattika:
English: - The active substance is ribavirin 200 mg. - The other ingredients are microcrystalline cellulose, lactose monohydrate (40 mg), croscarmellose sodium, magnesium stearate.
Maltese: - Is-sustanza attiva hi ribavirin 200 mg - Is-sustanzi l-oħra huma microcrystalline cellulose, lactose monohydrate (40 mg), croscarmellose sodium, magnesium stearate.
English: SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com
Maltese: SIA Merck Sharp & Dohme Latvija Tel: +371 67364224
English: Ribavirin was active in the Balb/3T3 in vitro transformation assay.
Maltese: Ribavirin kien attiv fit-test tat-trasformazzjoni tal-Balb/3T3 in vitro.
English: EU/1/99/107/001 84 hard capsules EU/1/99/107/005 112 hard capsules EU/1/99/107/002 140 hard capsules EU/1/99/107/003 168 hard capsules
Maltese: EU/1/99/107/005 112-il kapsula iebsa EU/1/99/107/002 140 kapsula iebsa EU/1/99/107/003 168 kapsula iebsa
English: Citric acid, anhydrous Sodium benzoate
Maltese: Sodium citrate Citric acid, anhydrous Sodium benzoate Glycerol
English: Positive
Maltese: Negattiv
English: 2, rue Louis Pasteur 14200 Hérouville-Saint-Clair France
Maltese: 2, rue Louis Pasteur 14200
English: Rebetol contains sucrose and sorbitol
Maltese: Rebetol fih sucrose u sorbitol
English: As the solution fills the syringe, you will see the numbers on the rod go up, such as 1.5 mL, 2.0 mL, 2.5 mL, etc.
Maltese: Fil-waqt li s-soluzzjoni timla s-siringa, ara n-numri tal-bastun telgħin, bħall 1.5 mL, 2.0 mL, 2.5 mL eċċ.
English: Ribavirin has two pathways of metabolism: 1) a reversible phosphorylation pathway; 2) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxyacid metabolite.
Maltese: Ribavirin għandu żewġ passaġġi ta' metaboliżmu: 1) passaġġ riversibbli tal-fosforilazzjoni; 2) degradazzjoni li tinvolvi t-tneħħija ta' ribose (deribosylation) u amide hydrolysis li tipproduċi metabolit triazole carboxyacid.
English: Date of first authorisation: 25 January 2005 Date of latest renewal: 23 April 2009
Maltese: Data tal-aħħar tiġdid: 23 ta' April 2009
English: The capsule shell imprint contains shellac, propylene glycol, ammonium hydroxide, colouring agent (E 132).
Maltese: It-timbru tal-qoxra tal-kapsula fih shellac, propylene glycol, ammonium hydroxide, colouring agent (E
English: A total of 118 patients were enrolled: 57 % male, 80 % Caucasian, and 78 % genotype 1, 64 %  12 years of age.
Maltese: Kienu reklutati total ta' 118-il pazjent: 57 raġel, 80 % Kawkażi, u 78 % ġenotip 1, 64 % ≤ 12-il sena.
English: In clinical trials of 118 children and adolescents 3 to 16 years of age treated with combination therapy of interferon alfa-2b and Rebetol, 6 % discontinued therapy due to adverse reactions.
Maltese: Fi provi kliniċi b'118-il tifel u tifla u adolexxenti ta' 3 sa 16-il sena kkurati b'terapija kombinata b'interferon alfa-2b u Rebetol, 6 % waqqfu t-terapija minħabba reazzjonijiet avversi.
English: The capsule shell contains gelatine, titanium dioxide.
Maltese: Il-qoxra tal-kapsula fiha gelatine, titanium dioxide.
English: Sorbitol liquid (crystallising) Propylene glycol
Maltese: Sorbitol liquid (crystallising) Propylene glycol Ilma ppurifikat
English: Arthralgia, myalgia, musculoskeletal pain
Maltese: Artralġja, mijalġja, uġigħ muskolu-skeletriku
English: Carrat F, Bani-Sadr F, Pol S et al. JAMA 2004; 292(23): 2839-2848.
Maltese: JAMA 2004; 292(23): 2839-2848.
English: Ulcerative colitis*
Maltese: Kolite ulċerattiva*
English: Peripheral ischaemia*
Maltese: Iskemija periferika*